Filters
Results for Chemicals & Small Molecules ( 98423 )
Envafolimab (ASC 22; KN 035), a recombinant humanized single-domain anti-PD-L1 antibody, integrates the anti-PD-L1 domain with the Fc fragment of the human IgG1 antibody. It inhibits the PD-L1 and PD-1 interaction with an IC50 of 5.25 nM, indicating its research potential for solid tumors [1] [2] [3].
Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].